BioCentury | Sep 19, 2011
Company News

Via Science, Brigham and Women's Hospital deal

...using data from over 18,000 patients with congestive heart failure (CHF). Terms were not disclosed. Via Science Inc....
BioCentury | Aug 15, 2011
Company News

Via Science, Bristol-Myers deal

...therapies for specific genetic and phenotypes to optimize individualized patient outcomes. Details were not disclosed. Via Science Inc....
BioCentury | Jul 18, 2011
Company News

Via Science, National Cancer Institute deal

...response to drug treatments for the development of more effective treatments. Details were not disclosed. Via Science Inc....
Items per page:
1 - 3 of 3
BioCentury | Sep 19, 2011
Company News

Via Science, Brigham and Women's Hospital deal

...using data from over 18,000 patients with congestive heart failure (CHF). Terms were not disclosed. Via Science Inc....
BioCentury | Aug 15, 2011
Company News

Via Science, Bristol-Myers deal

...therapies for specific genetic and phenotypes to optimize individualized patient outcomes. Details were not disclosed. Via Science Inc....
BioCentury | Jul 18, 2011
Company News

Via Science, National Cancer Institute deal

...response to drug treatments for the development of more effective treatments. Details were not disclosed. Via Science Inc....
Items per page:
1 - 3 of 3